Pharmaceuticals, Biotechnology and Life Sciences
The new safety data is from the ESCAPE-TRD Phase 3b study, which showed esketamine NS demonstrated a significant increase in…
New subcutaneous, fixed-dose formulation of daratumumab reduces treatment time from hours to minutes, with comparable efficacy and fewer infusion-related reactions1,2…
Janssen has submitted a type II variation application to European Medicines agency, looking to get approved guselkumab, which could then…
BARCELONA, Spain–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of…
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human…
Janssen gets positive CHMP opinion for Spravato (esketamine) nasal spray for adults with treatment-resistant major depressive disorder, which, if approved…
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications.
The program facilitated by Johnson & Johnson Innovation will recruit data scientists to research high impact, data-science projects in healthcare…